At these concentrations, both the GSK2578215A (Fig. 3) and LRRK2-IN1 (Supplementary Figure 2) inhibitors reduced LRRK2 phosphorylation to similar extents in both the control and PD patient PBMCs for all four phosphorylation sites. The gene discussed is LRRK2; the disease is Parkinson disease.